Observational Study of Purinergic Signaling and the Postmenopausal Heart
This study is looking at how changes in the heart's signals (called purinergic signaling) might be linked to heart failure in women after menopause. Researchers want to understand why postmenopausal women have a higher risk of a type of heart failure called diastolic heart failure (when the heart has trouble filling with blood). They will compare differences between men and women by looking at heart tissue from patients having heart surgery. They will measure specific markers related to energy production and blood vessel growth in the heart. The study aims to enroll 500 participants, aged 30 to 88, who are undergoing cardiac surgery. This is an observational study, meaning researchers will only be looking at existing differences, not testing a new treatment.
- Study design
- This is an observational study comparing differences between men and women, with a planned enrollment of 500 participants.
- What's involved
- Participants will provide heart tissue during cardiac surgery. The study will then measure markers in this tissue at 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Measurements of markers will be taken at 6 months after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Purinergic Signaling and the Postmenopausal Heart
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Robina Matyal, MD · PRINCIPAL_INVESTIGATOR · Beth Israel Deaconess Medical Center, Professor of Anesthesia
- Simon Robson, MD, PhD · PRINCIPAL_INVESTIGATOR · Beth Israel Deaconess Medical Center,Vice Chair Research
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Comparative quantification of expression of CD39 and adenosinergic receptors6 months
Expression of CD39, ADORA2A and ADORA2B in cardiac tissue measured using Western blotting
- Comparative quantification of expression of PGC-1 alpha, mitochondrial markers6 months
Expression of PGC-1 alpha, AMPK and mitochondrial markers using Western blot
- Comparative quantification of expression of angiogenic markers6 months
Expression of angiogenic markers (PDGF, VEGF, Angiostatin)